Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/138336MUTATED TRNA FOR CODON EXPANSION
WO 02.07.2020
Int.Class C40B 40/06
CCHEMISTRY; METALLURGY
40COMBINATORIAL TECHNOLOGY
BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
40Libraries per se, e.g. arrays, mixtures
04Libraries containing only organic compounds
06Libraries containing nucleotides or polynucleotides, or derivatives thereof
Appl.No PCT/JP2019/051241 Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA Inventor SHINOHARA, Shojiro
In some embodiments, the present disclosure relates to a mutated tRNA in which the first position of the anti-codon has been changed into lysidine or agmatidine and a translation system containing the mutated tRNA. In a specific embodiment, the present disclosure provides a mutated tRNA which is capable of selectively translating codon NNA. In another embodiment, the present disclosure provides a translation system which is capable of translating two or three kinds of amino acids from one codon box. In still another embodiment, the present disclosure provides a novel synthesis method for lysidine diphosphate, agmatidine diphosphate and derivatives thereof.
2.WO/2020/138509MYOSTATIN SIGNAL INHIBITOR
WO 02.07.2020
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/JP2019/051651 Applicant NIPPON SHINYAKU CO., LTD. Inventor NAKAGAWA, Shinichiro
The present invention provides a new approach for inhibiting myostatin signaling by targeting ACVR2B at the mRNA level.
3.WO/2020/138543ORNITHINE DECARBOXYLASE MUTANT STRAIN AND APPLICATION THEREOF
WO 02.07.2020
Int.Class C12N 9/88
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
88Lyases (4.)
Appl.No PCT/KR2018/016764 Applicant CJ CHEILJEDANG CORPORATION Inventor KIM, Byung-Gee
The present invention relates to a generation method for an ornithine decarboxylase mutant strain, characteristics of the mutant strain, a gene encoding the ornithine decarboxylase mutant strain, and a method for producing putrescine using the generation method, the characteristics, and the gene. The present invention has effects of increasing productivity or production efficiency of putrescine and reducing costs in the purification of putrescine by suppressing a side reaction.
4.WO/2020/138919ORNITHINE DECARBOXYLASE VARIANT AND METHOD FOR PRODUCING PUTRESCINE BY USING SAME
WO 02.07.2020
Int.Class C12N 9/88
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
88Lyases (4.)
Appl.No PCT/KR2019/018404 Applicant CJ CHEILJEDANG CORPORATION Inventor LEE, Jaehun
The present application relates to: an ornithine decarboxylase or a protein variant thereof; a polynucleotide encoding same; a microorganism containing same; and a method for producing putrescine by using same. The present invention achieves effects of increasing the productivity, production efficiency or production selectivity of putrescine, and reducing costs during putrescine purification by suppressing side reactions.
5.WO/2020/139031CRISPR-CAS-BASED COMPOSITION FOR GENE CORRECTION
WO 02.07.2020
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/KR2019/018627 Applicant INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY Inventor CHOI, Je-Min
The present invention relates to a composition for enhancing the cell permeability and gene correction efficiency of a Cas protein and guide RNA, and in the case of currently used techniques for gene correction through CRISPR-Cas, intracellular injection in a complex form is difficult, stability has not been verified even with injection, efficiency is low, and there are off-target problems. However, when the composition for gene correction according to the present invention is used, the efficiency of intracellular delivery is remarkably high, off-target effects can be inhibited, and stability can be ensured, and thus the composition can be effectively used in gene therapy.
6.WO/2020/139279ACINETOBACTER BAUMANNII BACTERIOPHAGE MIKAB48 OR LYTIC PROTEIN DERIVED FROM THE BACTERIOPHAGE
WO 02.07.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/TR2019/051177 Applicant MIKROLIZ BIYOTEKNOLOJI SAN. VE TIC. LTD. STI. Inventor COTAK, Medine
The invention discloses a novel Acinetobacter baumannii bacteriophage and lytic protein derived from the bacteriophage. The bacteriophage and lytic protein derived from the bacteriophage both have strong in vitro antibacterial effects on pan-drug resistant Acinetobacter baumannii clinical strains providing experimental basis for developing a preparation for preventing and treating infections caused by Acinetobacter baumannii containing the bacteriophage or lytic protein thereof.
7.WO/2020/139852COMBINATIONS OF ENGINEERED ANTIMICROBIAL PROBIOTICS FOR TREATMENT OF GASTROINTESTINAL TRACT PATHOGENS
WO 02.07.2020
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
Appl.No PCT/US2019/068400 Applicant GENERAL PROBIOTICS, INC. Inventor KAZNESSIS, Yiannis John
Embodiments herein relate to engineered antimicrobial probiotics for the treatment of gastrointestinal tract pathogens. In an embodiment, a composition for treatment of an animal is included. The composition can include a first genetically engineered bacterium comprising a first exogenous polynucleotide. The first exogenous polynucleotide can include a first heterologous promoter and a first polynucleotide that encodes a first antimicrobial protein. The composition can also include a second genetically engineered bacterium comprising a second exogenous polynucleotide. The second exogenous polynucleotide can include a second heterologous promoter and a second polynucleotide that encodes a second antimicrobial protein. The first heterologous promoter can be induced by one set of exogenous environmental conditions found in the gastrointestinal tract of the animal and the second heterologous promoter can be induced by a second set of exogenous environmental conditions found in the gastrointestinal tract of the animal. Other embodiments are also included herein.
8.WO/2020/133233PATHOGENIC MUTATION OF OSTEOGENESIS IMPERFECTA DISEASE AND DETECTION REAGENT THEREFOR
WO 02.07.2020
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/CN2018/124930 Applicant HUANG, Huan Inventor HUANG, Huan
Provided are a pathogenic mutation of osteogenesis imperfecta and a detection reagent therefor. For a mutant COL1A1 gene, single site mutation c.1822G>A (chr17:48270211) is related in the mutated COL1A1 gene, whereof the heterozygous mutation is pathogenic, the genetic mode is dominant inheritance, and for the amino acid change at p.Gly608Ser, the site mutation causes dyssynthesis of I-type collagen in connective tissue, so that a lesion is formed. Provided is a kit for detecting osteogenesis imperfecta, comprising a reagent for detecting the 1822bp-th site of a COL1A1 gene CDS or a reagent for detecting the 608-th amino acid site of a COL1A1 protein. The osteogenesis imperfecta disease can be diagnosed by detecting the pathogenic mutation (c.1822G>A on the COL1A1 gene).
9.WO/2020/133436METHOD AND CULTURE MEDIUM FOR INDUCING EMBRYONIC STEM CELL TO DIFFERENTIATE INTO ENDOMETRIAL GLANDULAR EPITHELIAL PRECURSOR CELL
WO 02.07.2020
Int.Class C12N 5/0735
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
073Embryonic cells or tissues; Foetal cells or tissues
0735Embryonic stem cells; Embryonic germ cells
Appl.No PCT/CN2018/125685 Applicant JIANG, Xiuxiu Inventor JIANG, Xiuxiu
Disclosed are a method and a culture medium for inducing a human embryonic stem cell to differentiate into an endometrial glandular epithelial precursor cell. The method comprises culturing an epithelial cell formed from induced proliferation of a human embryonic stem cell in a differentiation culture medium for an endometrial glandular epithelial precursor cell to induce the epithelial cell to differentiate into the endometrial glandular epithelial precursor cell, the differentiation culture medium for an endometrial glandular epithelial precursor cell comprising EGF, FBS, GlutaMAX and WNT3A. The method can induce a human embryonic stem cell to differentiate into an endometrial glandular epithelial precursor cell. The method is simple to operate and can produce, from a single embryonic stem cell clone, endometrial glandular epithelial precursor cells at high yield in the order of millions of cells and with a high purity of nearly 100%. The endometrial glandular epithelial precursor cells obtained from the method can be used for treating diseases associated with absence of endometrium, difficulty in endometrial hyperplasia, intrauterine adhesions, and early uterine abortion, among others.
10.WO/2020/135201ANTIBODY AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/126495 Applicant SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Inventor TIAN, Haijun
The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.